A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 5.72 USD -7.14% Market Closed
Market Cap: 208.3m USD

Armata Pharmaceuticals Inc
Net Change in Cash

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Armata Pharmaceuticals Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Net Change in Cash
-$22.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Change in Cash
-$1.6B
CAGR 3-Years
-67%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Net Change in Cash
$2.3B
CAGR 3-Years
90%
CAGR 5-Years
-8%
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Net Change in Cash
$434m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Change in Cash
-$300.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Change in Cash
$501.3m
CAGR 3-Years
103%
CAGR 5-Years
22%
CAGR 10-Years
51%
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
207m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
HIDDEN
Show

See Also

What is Armata Pharmaceuticals Inc's Net Change in Cash?
Net Change in Cash
-22.2m USD

Based on the financial report for Jun 30, 2025, Armata Pharmaceuticals Inc's Net Change in Cash amounts to -22.2m USD.

Back to Top